Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer : Phase II Trial of Dose Dense Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Upon determination of eligibility, patients will be receive both induction neo-adjuvant regimen and a postoperative adjuvant regimen:Induction Neo-adjuvant: Epirubicin + Gemcitabine + ABI-007 + PegfilgrastimPostoperative Adjuvant: Gemcitabine + ABI-007 + PegfilgrastimUpon completion of chemotherapy, all ER and/or PR+ patients will receive Tamoxifen or an aromatase inhibitor at physician discretion..

Medienart:

Klinische Studie

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

ClinicalTrials.gov - (2021) vom: 23. Nov. Zur Gesamtaufnahme - year:2021

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Breast Neoplasms
Inflammatory Breast Neoplasms
Medical Condition: Breast Cancer
Phase: Phase 2
Recruitment Status: Completed
Study Type: Interventional

Anmerkungen:

Source: Link to the current ClinicalTrials.gov record., First posted: September 19, 2005, Last downloaded: ClinicalTrials.gov processed this data on December 06, 2021, Last updated: December 08, 2021

Study ID:

NCT00193206
SCRI BRE 73

Veröffentlichungen zur Studie:

fisyears:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG000189898